Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05306288 · ClinicalTrials.gov registry record

CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in Lung

A clinical trial of Lung Cancer, sponsored by Delfi Diagnostics.

Active
Registry status
11,935
Enrollment target
20
Study locations

NCT05306288: Active study of Lung Cancer, sponsored by Delfi Diagnostics.

NCT05306288 is a study of Lung Cancer that is active but no longer recruiting, run by Delfi Diagnostics. The registered enrollment target is 11,935 participants, above the 907-participant average among 409 other Lung Cancer trials with a reported enrollment target (1216% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05306288, a study of Lung Cancer, is active but no longer recruiting, sponsored by Delfi Diagnostics.

ACTIVE NOT RECRUITING
Registry status
11,935 participants
Enrollment target
20
Study locations

Study Summary

CASCADE-LUNG is a multisite, prospective, observational, blood specimen collection study in the elevated-risk lung cancer screening population. The primary objective is to demonstrate the performance characteristics, including sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the DELFI Lung Cancer Screening Test (DLCST) for the detection of pathologically-confirmed lung cancer in a screening population using LDCT, pathology, and follow-up as the reference method.

Conditions Studied

Lung Cancer

Interventions

  • OTHER Blood Sample Collection

Study Locations (20)

California

  • Science 37 (nationwide digital enrollment) - Culver City
  • Providence Facey Medical Foundation - Mission Hills
  • Hoag Hospital - Newport Beach
  • Paradigm Clinical Research Center, Inc. - Redding
  • San Francisco VA - San Francisco
  • Clinical Research of California LLC - Walnut Creek

Florida

  • Advanced Research - Boynton Beach
  • Morton Plant Hospital - Clearwater
  • SIMEDHealth, LLC - Gainesville
  • Galenus Group - Lehigh Acres
  • Renstar Medical Research - Ocala
  • United Medical Research - Port Orange

Georgia

  • American Clinical Trials, LLC. - Acworth
  • Centricity Research Columbus Piedmont - Columbus
  • ClinCept, LLC - Columbus
  • Coastal Heritage Clinical Research - Hinesville

Colorado

  • SCL Health Research Institute, St. Mary's - Grand Junction
  • Paradigm Clinical Research Center - Wheat Ridge

Alabama

  • Cullman Clinical Trials - Cullman

Connecticut

  • Stamford Health - Stamford

Trial Details

FieldValue
Enrollment Target 11,935 participants
Start Date 2022-04-07
Est. Completion 2026-10-30

Sponsor

Delfi Diagnostics

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05306288

The ClinicalTrials.gov registry entry for NCT05306288 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 11,935 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 907-participant average among 409 other Lung Cancer trials with a reported enrollment target (1216% higher). The listed sponsor is Delfi Diagnostics, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Blood Sample Collection is the first listed.

NCT05306288 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT05306288 about?

NCT05306288 is a clinical study titled "CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in Lung". CASCADE-LUNG is a multisite, prospective, observational, blood specimen collection study in the elevated-risk lung cancer screening population. The primary objective is to demonstrate the performance characteristics, including sensitivity, specificity, positive predictive value (PPV) and negative pr...

What is the current status of trial NCT05306288?

This trial is currently active not recruiting. The enrollment target is 11,935 participants. The study started on 2022-04-07. Estimated completion is 2026-10-30.

What conditions does trial NCT05306288 study?

This clinical trial studies the following conditions: Lung Cancer.

What interventions are being tested in trial NCT05306288?

The interventions under investigation include: Blood Sample Collection (OTHER).

Who is sponsoring clinical trial NCT05306288?

This trial is sponsored by Delfi Diagnostics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05306288 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.